BioNano Genomics
This organisation’s record, built from what each source attests and blank where none does.
TypeOtherHQUS
Reading the record…
This organisation’s record, built from what each source attests and blank where none does.
Reading the record…
Everything below is drawn from what the record carries for this organisation: its documented parents, the constraints that reach it, and the relationships and sites recorded against it. Each claim carries its source on the same line, and a blank means the record holds nothing.
Each hop carries its data source, source URL (where one exists), as-of date, and confidence label on the same line as the parent name. When two sources name different parents for the same hop, both render as alternates; the walker picks no winner.
Starting entity. The walker climbs from here through documented parent / subsidiary edges.
Chain-of-title terminates at BioNano Genomics (CIK 1411690). No further parent is documented. For a public filer that means ultimate beneficial ownership is the dispersed float; for a state-linked entity, that the chain has reached the sovereign apex.
Dollar flows are annual figures from the fiscal year labelled on the row, drawn from SEC segment and >10%-customer disclosures, re-derived company disclosures, or a licensed supply-chain database; per-row source and authority tier on hover. A row without a year means the source does not state the period. Disclosures older than 5 years are tagged historical and ordered below current rows: they record what was disclosed then, and the counterparty may since have been acquired or dissolved. The 3-month Pearson r comes from a licensed supply-chain database; correlation is a coupling proxy for shared market sensitivity, and it is not a causal channel. Sole-source edges are flagged inline.
The records above join to the platform's analytical surfaces. Each link carries BioNano Genomics's own numbers into the tool that acts on them.
0 upstream · 1 downstream. The interactive graph opens with BioNano Genomics selected, and the cascade simulator propagates seed disruptions across this same edge set, weighted by the curator's substitutability assessment.
Facilities, sovereign-AI programs, export-control posture, and the announced-versus-deployed reality gap for the country.
One licensed feed is absent here: the corporate-financials extract behind this profile (geographic revenue, segment mix, capital allocation), which covers a loaded set of listed companies that BioNano Genomics is not among; the gap is in coverage, not in the record. The public industry classification (SIC, NAICS) is absent as well, and neither absence speaks to what Scrutica holds on BioNano Genomics elsewhere. Coverage rules in the methodology.